X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (951) 951
humans (734) 734
hepatitis c virus (537) 537
ns3 protease (408) 408
antiviral agents - pharmacology (359) 359
virology (357) 357
viral nonstructural proteins - antagonists & inhibitors (350) 350
biochemistry & molecular biology (349) 349
viral nonstructural proteins - metabolism (340) 340
proteases (328) 328
hepatitis c (326) 326
hepacivirus - drug effects (320) 320
viruses (318) 318
pharmacology & pharmacy (311) 311
ns3 (307) 307
antiviral agents (287) 287
hepacivirus - genetics (276) 276
viral nonstructural proteins - genetics (276) 276
crystal-structure (270) 270
virus diseases (267) 267
chemistry, medicinal (266) 266
animals (263) 263
protease inhibitors (262) 262
hcv (247) 247
replication (243) 243
viral nonstructural proteins - chemistry (238) 238
hepacivirus - enzymology (228) 228
serine-protease (216) 216
hepatitis-c virus (208) 208
in-vitro (208) 208
protease inhibitors - pharmacology (208) 208
proteins (204) 204
health aspects (199) 199
infection (199) 199
models, molecular (187) 187
antiviral agents - therapeutic use (186) 186
antiviral agents - chemistry (184) 184
hepatitis (182) 182
analysis (179) 179
inhibitors (178) 178
dengue (165) 165
microbiology (163) 163
dengue virus (155) 155
chemistry, organic (152) 152
amino acid sequence (151) 151
genotype (150) 150
serine endopeptidases - metabolism (148) 148
interferon (147) 147
ribavirin (146) 146
discovery (144) 144
molecular sequence data (144) 144
structure-activity relationship (144) 144
protease inhibitors - chemistry (143) 143
infectious diseases (142) 142
protease (142) 142
ns3 protein (137) 137
hepatitis c - drug therapy (136) 136
hepatitis c, chronic - drug therapy (133) 133
gastroenterology & hepatology (128) 128
drug discovery (126) 126
ns2b-ns3 protease (126) 126
binding sites (124) 124
protease inhibitor (124) 124
drug design (123) 123
ns3/4a protease (121) 121
serine endopeptidases - chemistry (120) 120
article (119) 119
protein binding (118) 118
rna (116) 116
virus replication - drug effects (115) 115
cell line (113) 113
dependent rna-polymerase (112) 112
digestive system diseases (112) 112
male (107) 107
mutation (107) 107
west-nile-virus (106) 106
drug resistance, viral (104) 104
hepatitis c - virology (104) 104
identification (104) 104
binding (101) 101
resistance (101) 101
infections (98) 98
antiviral activity (96) 96
telaprevir (96) 96
research (93) 93
domain (92) 92
female (92) 92
genetic aspects (92) 92
inhibitor (92) 92
dengue virus - enzymology (91) 91
drug resistance (91) 91
ns3 helicase (91) 91
treatment-naive patients (90) 90
biophysics (88) 88
molecular structure (87) 87
rna helicases - metabolism (87) 87
ns3 protease inhibitor (86) 86
proteinase (86) 86
protein conformation (85) 85
biochemical phenomena, metabolism, and nutrition (84) 84
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1684) 1684
Chinese (7) 7
French (4) 4
Japanese (2) 2
Portuguese (2) 2
German (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 2011, Volume 55, Issue 1, pp. 192 - 206
Journal Article
Hepatology, ISSN 0270-9139, 12/2008, Volume 48, Issue 6, pp. 1769 - 1778
Journal Article
Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 142, Issue 6, pp. 1340 - 1350.e1
Development of robust cell culture models for hepatitis C viral infection has greatly increased our understanding of this virus and its life cycle. This... 
Gastroenterology and Hepatology | Protease Inhibitors | NS5A Inhibitors | Host Targeted Anti-Virals | NS5B Inhibitors | RNA REPLICATION | INTERFERON-LAMBDA | COMBINATION THERAPY | NS5A INHIBITOR | GENETIC-VARIATION | REPLICATION COMPLEX INHIBITOR | ANTIVIRAL ACTIVITY | HCV | GASTROENTEROLOGY & HEPATOLOGY | NS3/4A PROTEASE INHIBITOR | IN-VITRO RESISTANCE | Hepacivirus - drug effects | Virus Replication - drug effects | Antiviral Agents - pharmacology | Drugs, Investigational - adverse effects | Drugs, Investigational - pharmacology | Antiviral Agents - therapeutic use | Humans | Drug Resistance, Viral | Drugs, Investigational - therapeutic use | Hepacivirus - genetics | Treatment Outcome | Clinical Trials as Topic | Interferons - therapeutic use | Hepatitis C, Chronic - drug therapy | Hepacivirus - metabolism | Serine Proteinase Inhibitors - therapeutic use | Cyclophilins - antagonists & inhibitors | Animals | Time Factors | Antiviral Agents - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Drug Therapy, Combination | Viral Nonstructural Proteins - antagonists & inhibitors | Drugs | Antiviral agents | Chemical tests and reagents | Virus diseases | Proteins | Hepatitis | MicroRNA | Interleukins | Protease inhibitors | Viral proteins | Proteases | Analysis | Product development | Hepatitis C virus | Health aspects
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 07/2017, Volume 61, Issue 7
Although genotype 4 (GT4)-infected patients represent a minor overall percentage of the global hepatitis C virus (HCV)-infected population, the high prevalence... 
Resistance | Antiviral agents | NS5A | Antiviral | Drug resistance mechanisms | HCV | Elbasvir | Hepatitis C virus | NS3/4A | Genotype 4 | Grazoprevir | MK-8742 | EFFICACY | antiviral agents | MK-5172 | MICROBIOLOGY | IDENTIFICATION | COMBINATION | elbasvir | resistance | DISCOVERY | REPLICATION | drug resistance mechanisms | GENOTYPE 1A | antiviral | hepatitis C virus | grazoprevir | PHARMACOLOGY & PHARMACY | INFECTION | MUTATIONS | genotype 4
Journal Article